Shaf Keshavjee | Professor
BA (Toronto), MD (Toronto), MASc (Toronto), LMCC
- Division of Thoracic Surgery, Department of Surgery
- Surgeon-in-Chief, James Wallace McCutcheon Chair in Surgery,Program Medical Director, Surgical Service and Critical Care, University Health Network
- Director, Toronto Lung Transplant Program, Toronto General Hospital and SickKids Hospital
- Senior Scientist, Division of Experimental Therapeutics, and McEwen Centre for Regenerative Medicine, University Health Network
- Institute of Biomaterials & Biomedical Engineering
Toronto Medical Discovery Tower
200 Elizabeth Street, 9th Floor, Room 9N946
Toronto, Ontario M5G 2C4 Canada
+1 416 340-7639 (clinical)
+1 416 340-4010 (admin)
Clinical outcomes & Lung Injury & Gene Therapy in Lung Transplantation. Current research includes:
1) Injured Donor Lung Repair
We have recently developed a method for stable normothermic ex vivo lung perfusion. Using this system, we are developing therapeutics to repair donor lungs currently deemed unsuitable for repair. Among others, we are currently developing IL-10 gene therapy as one such therapeutic technique using large animal models and rejected human lungs.
2) Mechanisms in bronchiolitis obliterans syndrome
Bronchiolitis obliterans syndrome is the major limitation to long term survival of lung transplant recipients. Using an intrapulmonary tracheal transplant model developed in this laboratory, we are studying the mechanisms which lead to the development of this syndrome. This model has recently been successfully performed in the mouse. We anticipate that the use of knockout mice together with this system will further our understanding of the development of this syndrome.
3) Identification of biomarkers for improved donor assessment
Currently, assessment of the suitability of a donor lung for transplantation is a clinical judgment. Using microarray technology and our donor lung tissue bank, we seek to identify biomarkers which predict lung function and suitability for transplantation. Ultimately, we hope to use these biomarkers clinically to both identify suitable lungs and to recognize lung repair following therapeutics during ex vivo lung perfusion.